ASPIRA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Aspira Pathlab & Diagnostics Along With Two Other Designated Partners Incorporated Llp
April 4 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:
ASPIRA PATHLAB & DIAGNOSTICS LTD - CO ALONG WITH TWO OTHER DESIGNATED PARTNERS INCORPORATED LLP
Source text for Eikon: ID:nBSE8FwGRB
Further company coverage: ASPR.BO
(([email protected];))
April 4 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:
ASPIRA PATHLAB & DIAGNOSTICS LTD - CO ALONG WITH TWO OTHER DESIGNATED PARTNERS INCORPORATED LLP
Source text for Eikon: ID:nBSE8FwGRB
Further company coverage: ASPR.BO
(([email protected];))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Aspira Pathlab&Diagn do?
Aspira Pathlab & Diagnostics Limited specializes in operating laboratories for a wide range of pathological investigations across multiple branches of healthcare.
Who are the competitors of Aspira Pathlab&Diagn?
Aspira Pathlab&Diagn major competitors are Invicta Diagnostic, Nephro Care India, Chandan Healthcare, Suraksha Diagnostic, Krsnaa Diagnostics, Vimta Labs, Thyrocare Tech.. Market Cap of Aspira Pathlab&Diagn is ₹64 Crs. While the median market cap of its peers are ₹1,428 Crs.
Is Aspira Pathlab&Diagn financially stable compared to its competitors?
Aspira Pathlab&Diagn seems to be less financially stable compared to its competitors. Altman Z score of Aspira Pathlab&Diagn is 9.23 and is ranked 5 out of its 8 competitors.
Does Aspira Pathlab&Diagn pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aspira Pathlab&Diagn latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aspira Pathlab&Diagn allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Aspira Pathlab&Diagn balance sheet?
Balance sheet of Aspira Pathlab&Diagn is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aspira Pathlab&Diagn improving?
Yes, profit is increasing. The profit of Aspira Pathlab&Diagn is ₹3.4 Crs for TTM, ₹2.02 Crs for Mar 2025 and -₹2.67 Crs for Mar 2024.
Is the debt of Aspira Pathlab&Diagn increasing or decreasing?
The net debt of Aspira Pathlab&Diagn is decreasing. Latest net debt of Aspira Pathlab&Diagn is -₹2.96 Crs as of Mar-25. This is less than Mar-24 when it was -₹1.66 Crs.
Is Aspira Pathlab&Diagn stock expensive?
Aspira Pathlab&Diagn is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Aspira Pathlab&Diagn is 26.84, while 3 year average PE is 16.43. Also latest EV/EBITDA of Aspira Pathlab&Diagn is 13.06 while 3yr average is 21.78.
Has the share price of Aspira Pathlab&Diagn grown faster than its competition?
Aspira Pathlab&Diagn has given better returns compared to its competitors. Aspira Pathlab&Diagn has grown at ~2.21% over the last 1yrs while peers have grown at a median rate of -16.96%
Is the promoter bullish about Aspira Pathlab&Diagn?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Aspira Pathlab&Diagn is 18.39% and last quarter promoter holding is 18.39%.
Are mutual funds buying/selling Aspira Pathlab&Diagn?
There is Insufficient data to gauge this.
